



Email Subject: Important: Discontinuation of Cipralex MELTZ® (escitalopram) Orodispersible Tablets in Canada

Body of email

Lundbeck Canada Inc.

April 6th, 2018

Re: Discontinuation of Cipralex MELTZ® (escitalopram) Orodispersible Tablets in Canada

Dear Healthcare Professional,

After careful consideration, Lundbeck Canada Inc. (Lundbeck) has made the decision to discontinue the distribution of Cipralex MELTZ® (escitalopram) Orodispersible Tablets in Canada. Based on historical demand, we expect our current inventory to be depleted by **June 1st, 2018**. This decision was not triggered by a safety issue.

Please note that all other formulations and dosages of Cipralex® will continue to be supplied by Lundbeck Canada. Only Cipralex MELTZ® is being discontinued.

The following 2 formats of Cipralex MELTZ® will be discontinued:

Product:	Generic Name	Format	Product Code	DIN	UPC Code
Cipralex MELTZ 10mg blister pack	Escitalopram	30 Orodispersible tablets	135614	02391449	6-26873-35614-5
Cipralex MELTZ 20mg blister pack	Escitalopram	30 Orodispersible tablets	135613	02391457	6-26873-35613-8

Lundbeck previously communicated this change in October 2017 to give healthcare professionals, patients and families as much notice as possible so that Cipralex MELTZ® patients have ample time to shift to an acceptable alternative therapy. This is the FINAL NOTICE to Healthcare Professionals in Canada.

Lundbeck Canada will do the following to help patients & health care professionals in Canada:

- Access to Lundbeck's Medical Information team at 1-866-880-4636 or by e-mail at canadamedicalinformation@lundbeck.com to address medical questions or concerns.
- Distribution of a discontinuation letter to a comprehensive list of physicians, pharmacists and relevant stakeholders (patient organizations etc.) throughout Canada (first in October 2017 and now in April 2018), providing significant lead time to enable a carefully planned treatment transition plan.
 - Relevant patient advocacy organizations will be encouraged to share this notice for use in on- and offline communications materials, as appropriate.



- Outreach to pharmaceutical wholesalers.
- Inform provincial payers and private insurers.

If you have any additional questions about product availability or ordering, please contact Lundbeck Customer Service at **1-866-610-8338** or by email at CanadaCustomerService@Lundbeck.com.

Sincerely,

Original Signatures on File

Jean Proulx
Senior Director, Medical & Regulatory Affairs
Lundbeck Canada Inc.

Sylvie Pilon
Vice-President & General Manager
Lundbeck Canada Inc.